Read more
6:01 PM · 13 April 2021

Moderna stock rose 7% after FDA halt use of JNJ vaccine

-
-
Open account Download free app
-
-
Open account Download free app

The news that the Johnson & Johnson (JNJ.US) vaccine would be paused appeared to be beneficial for Moderna (MRNA.US) which shares gained more than 7% following FDA announcement. The drugmaker has also issued a statement saying that data indicates its COVID-19 vaccine is not associated with cerebral venous sinus thrombosis ("CVST") or other thrombotic events. Moderna announced that assessment was made based on safety data through March 22 of more than 64.5M doses administered worldwide.

Moderna (MRNA.US) stock launched today's session with a bullish price gap and is currently testing the upper limit of the descending channel which coincides with 50 SMA (green line). Source: xStation5

27 March 2026, 6:24 PM

Anthropic leak and a cybersecurity sell-off

27 March 2026, 5:22 PM

Unity up 10% 🚨 A revolution at the company?

27 March 2026, 3:31 PM

US OPEN: Wall Street declines deepens

27 March 2026, 3:14 PM

US100 slumps 1.5% 🚩 Anthropic Claude pressures Nasdaq again

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits